Predictors of seroconversion after coronavirus disease 2019 vaccination

Chiarella, Sergio E.; Jenkins, Sarah M.; Smith, Carin Y.; Prasad, Vikas; Shakuntulla, Fnu; Ahluwalia, Vaibhav; Iyer, Vivek N.; Theel, Elitza S.; Joshi, Avni Y.

doi:10.1016/j.anai.2022.05.026

Cited by 3 publications

(2 citation statements)

References 39 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-N IgG antibody seroprevalence was significantly higher in those under 60 following BBIBP-CorV vaccination (Cohort II). The same age pattern in anti-S IgG antibody levels after vaccination with BBIBP-CorV and other available vaccines was observed in another Serbian population (Petrovic et al, 2022) as well as in other populations (Badano et al, 2022;Chiarella et al, 2022). In addition, individuals over 60 exhibited a lower occurrence of silent SARS-CoV-2 infection.…”

Section: Discussionsupporting

confidence: 70%

Silent SARS-CoV-2 infection: seroprevalence study of SARS-CoV-2 anti- nucleocapsid IgG antibodies in Kragujevac, Serbia

Cicaric,

Canovic,

Stojkovic

et al. 2023

Acta Virol.

View full text Add to dashboard Cite

Serological testing is a powerful tool for analyzing the infectious disease burden landscape. Therefore, this study aimed to determine the seroprevalence against SARS-CoV-2 in the population of the municipality of Kragujevac, Serbia, with a particular reference to silent infections. A total of 4,804 participants over 19 years of age were randomly sampled for population-based seroprevalence research. Anti-N IgG antibodies were measured using rapid serological tests (UNscience®). The population was divided into four Cohorts, according to the history of SARS-CoV-2 infection and vaccination status with the whole inactivated virus vaccine BBIBP-CorV (Vero Cell®, Sinopharm), as follows: Cohort I—confirmed SARS-CoV-2 infection, not vaccinated with the BBIBP-CorV vaccine; Cohort II—without confirmed SARS- CoV-2 infection, vaccinated with the BBIBP-CorV vaccine; Cohort III—confirmed SARS-CoV-2 infection, vaccinated with the BBIBP-CorV vaccine; Cohort IV—without confirmed SARS-CoV-2 infection, not vaccinated with the BBIBP-CorV vaccine (silent immunization). Cohorts I and IV included patients vaccinated with vaccines other than the BBIBP-CorV vaccine. The results showed that the overall prevalence of anti-N IgG antibodies was 56.5%, with the highest seroprevalence in Cohort III at 85.8%. In Cohort IV, the prevalence of anti-N IgG antibodies was 40.7%, attributed to silent immunization. The results also suggest that the prevalence of anti-N IgG antibodies decreased over time but remained detectable for more than 12 months in Cohort I. Since currently, there is no data on silent infection frequency in our country, these findings may provide insight into the extent of silent infections in the Serbian population.

show abstract

Section: Discussionsupporting

confidence: 70%

Silent SARS-CoV-2 infection: seroprevalence study of SARS-CoV-2 anti- nucleocapsid IgG antibodies in Kragujevac, Serbia

Cicaric,

Canovic,

Stojkovic

et al. 2023

Acta Virol.

View full text Add to dashboard Cite

show abstract

“…Older individuals, mostly more than 60 years old, experienced higher seronegativity after taking two doses of almost any type of COVID-19 vaccines, including CoronaVac, AstraZeneca, and Moderna ( Fonseca et al, 2022 ; Chiarella et al, 2022 ; Malagón-Rojas et al, 2022 ). The seronegativity might happen due to immunescence, which may decrease the immune response due to the reduction of T-cell proliferation, naïve T-cell population, cytokine production, and antigen recognition ( Fulop et al, 2009 ).…”

Section: Discussionmentioning

confidence: 99%

Seroprevalence of SARS-CoV-2 anti-spike IgG antibody among COVID-19 vaccinated individuals residing in Surabaya, East Java, Indonesia

Megasari,

Yamani,

Juniastuti

et al. 2023

PeerJ

View full text Add to dashboard Cite

Background To limit the SARS-CoV-2 transmission, the Indonesian government launched a COVID-19 vaccination program in January 2021. Studies on the clinical treatment and implementation of COVID-19 vaccination have shown promising results; however, it is necessary to estimate the effectiveness of the vaccines. With the ongoing COVID-19 pandemic, studies have highlighted the impact of COVID-19 vaccines, especially CoronaVac, on Indonesian healthcare workers. To get a better picture of how the vaccines work in Indonesia, it is necessary to estimate the prevalence of SARS-CoV-2 anti-S IgG antibody induced by the COVID-19 vaccine in individuals who have already received two-to-three doses of vaccines. Materials and Methods Four-hundred and ninety-six whole-blood samples were collected from participants residing in Surabaya, East Java, Indonesia, who received a minimum of a two-dose COVID-19 vaccine. Serums were then isolated from the blood and subjected to detect SARS-CoV-2 anti-S IgG antibodies using a lateral flow immunochromatographic assay. Results The prevalence of positive anti-S-IgG antibodies was 91.7% (455/496) in all participants receiving a minimum of a two-dose COVID-19 vaccine. As many as 209 (85.3%) and 141 (96.6%) participants were seropositive for receiving CoronaVac and AstraZeneca, respectively. Meanwhile, all participants receiving two-dose CoronaVac with one booster dose of Moderna (105/100%) were seropositive (p < 0.05). Age, comorbidity, and time after the last vaccine were significantly correlated with seropositivity (p < 0.05). Conclusion Different vaccines might produce different antibody responses. Adopting a stronger policy regarding the administration of booster doses might be beneficial to elicit positive anti-S-IgG antibodies, especially among older individuals, those with comorbid diseases, and those with a longer time after the second vaccination dose.

show abstract

COVID-19 Vaccination in Patients with Gastrointestinal Cancer Receiving Chemotherapy

Lee

Kim

2022

JDCR

View full text Add to dashboard Cite

show abstract

Predictors of seroconversion after coronavirus disease 2019 vaccination

Cited by 3 publications

References 39 publications

Silent SARS-CoV-2 infection: seroprevalence study of SARS-CoV-2 anti- nucleocapsid IgG antibodies in Kragujevac, Serbia

Silent SARS-CoV-2 infection: seroprevalence study of SARS-CoV-2 anti- nucleocapsid IgG antibodies in Kragujevac, Serbia

Seroprevalence of SARS-CoV-2 anti-spike IgG antibody among COVID-19 vaccinated individuals residing in Surabaya, East Java, Indonesia

COVID-19 Vaccination in Patients with Gastrointestinal Cancer Receiving Chemotherapy

Contact Info

Product

Resources

About